Use the Share Register services in our Stockholders' Portal:
Results from the Phase III CORRECT study with regorafenib in patients with metastatic colorectal cancer were presented as a late breaking abstract in an oral abstract session on January 21 (2:30 PM - 4:00 PM Pacific Time) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA, U.S. On this occasion we held a conference call for investors and analysts.
Let the Bayer magazine take you on a multimedia discovery tour! Read fascinating stories about the things that are happening now in the world of Bayer. Interactive reports take you behind the scenes of innovative products, Bayer’s social commitment and the latest research findings.
On-demand recording of the Q3 2011 Investor Conference Call
Presentation Charts 
PDF / 377 KB 
collectQ3_2011_ConferenceCall_2011-10-27_Redecharts.pdf Q3 2011 Investor Conference Call Presentation Chartspdf
Financial Report as of September 30, 2011 PDF / 2.07 MB collectQB_2011_3_e.pdf Financial Report as of September 30, 2011pdf
Q3 2011 Analyst and Investor Briefing PDF / 379 KB collectBayer_Q3_2011_Analyst_and_Investor_Briefing.pdf Q3 2011 Analyst and Investor Briefingpdf
Service for Investors and Analysts:
Download all documents on our Third Quarter 2011 results in one ZIP file:
ZIP / 2.86 MB collectBayer_Q3_2011_All-in-One_en.zip Q3 2011 All in One Download PackageZIP
You are leaving the Bayer AG website.
Bayer AG is not responsible for the information on the website to which you are linking.
